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Review Article
Diagnosis and Treatment of Sexual Dysfunctions in Late-Onset 
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Testosterone is the principal androgen in the human male. The decline of testosterone 
with aging was recognized to be associated with a number of symptoms and signs that 
reduce the quality of life and that may even have severe, debilitating consequences. 
Clinically, late-onset hypogonadism (LOH) is diagnosed by use of biochemical and clin-
ical measures. Despite published guidelines and recommendations, however, un-
certainty surrounds the profile of clinical symptoms as well as the biochemical thresh-
old of diagnosis. Clinicians should be aware of these shortcomings while adhering to 
the guidelines. Current treatment methods are centered on restoring testosterone to 
mid to lower levels of young men with natural testosterone replacements. Although 
recent studies have highlighted possible additional benefits involving improvement of 
systemic disorders, the goal of treatment is to improve sexual function, while observing 
for adverse effects in the prostate. Overall, the problem of LOH in debilitating the qual-
ity of life and well-being is real, and by following proper guidelines with attentiveness 
to the results of treatment trials, testosterone replacement therapy presents a safe and 
effective treatment option.
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INTRODUCTION
Testosterone is the principal androgen synthesized in the 
testis and the adrenal cortex in men. Its major physiologic 
roles include the development of the normal male, as well 
as maintenance of many male characteristics, including 
muscle mass, strength, bone mass, libido, potency, and 
spermatogenesis. The classic effects of testosterone re-
placement therapy were first noted in Brown-Sequard’s 
self-injection of fluid extracted from the testicles of dogs 
and guinea pigs before the Societe de Biologie in Paris, 
1889. He reported increased physical strength, mental 
abilities, and appetite [1]. Although his claims were never 
substantiated, his experiment led to a rash of endocrino-
logic research. Recent years have seen a revival in interest 
in the rejuvenating properties of testosterone. Epidemiolo-
gic studies have found a decrease of serum testosterone 
with normal aging [2,3]. Aging itself is typically associated 
with lack of energy, reduced strength, loss of libido,  and 
decreased sexual performance; many of these symptoms 
are similar to the presentation of testosterone deficiency 
[4,5]. A number of guidelines have since been published in 
an attempt to define the condition and to recommend ap-
propriate treatment [6,7]. However, much confusion re-
mains as to the appropriate approach to the diagnosis and 
treatment of late-onset hypogonadism (LOH).
LATE-ONSET HYPOGONADISM
1. Difficulty in defining the clinical syndrome of late-onset 
hypogonadism
The decrease of serum testosterone with age has been wide-
ly documented. Cross-sectional studies, such as the 
Massachusetts Male Aging Study, showed a 0.8% per year 
decline with total testosterone and a 2% per year decrease 
with bioavailable testosterone [2]. Longitudinal follow-up Korean J Urol 2011;52:725-735
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showed a decline of 1.6% per year with total testosterone 
and 2% to 3% per year for bioavailable testosterone [3]. 
However, the clinical milieu of the age-related decrease in 
testosterone is varied in both its presentation and 
significance. 
Aging is typically associated with a decline in sexual 
activity. However, these changes have not been well 
documented. Recently, large cross-sectional studies have 
described a sharp decrease in sexual activity with old age 
[8,9]. Whereas 73% of respondents aged 57 to 64 years re-
ported sexual activity, only 26% were sexually active by 75 
to 85 years of age. Male responders in the survey reported 
a steady decline in sexual interest with increasing age, 
from 28.2% to 24.2%, but showed larger changes in inability 
to climax, from 16.2% to 33.2%, and erectile dysfunction 
(ED), from 30.7% to 43.5%. Although decrease in sexual in-
terest may accompany ED, the survey also showed that sex-
ual activity not requiring vaginal penetration also showed 
an abrupt decrease [8]. Another large-scale survey showed 
that an isolated category of ‘thinking about sex’ decreased 
abruptly for respondents replying ‘every day,’ from about 
40% for men in their 40s to about 12% for men in their 70s; 
respondents who replied that they thought about sex ‘never 
or less than once a month’ increased from about 2% for men 
in their 40s to about 36% for men in their 70s [9]. These data 
suggest that not only the physical function of sexuality but 
also its mental appetite is severely hindered with age.
The results of studies identifying these patients with 
evaluation of serum testosterone levels concurred with the 
general presentation of decreased sexual activity but de-
scribed a divergence between erectile function and libido 
in their specificity [2,10,11]. The Massachusetts Male 
Aging Study confirmed that, in general, testosterone levels 
decreased with erectile function and libido [2,11]. The 
Boston Area Community Health Survey showed that, 
whereas ED was more prevalent in the overall population 
than decreased libido, the proportion of patients with de-
creased libido was higher among patients with decreased 
total and free testosterone [10]. The recent European Male 
Aging Study showed that, although sexual symptoms were 
all associated with age to some degree, after factoring for 
age, ED was also more dependent than libido on the pres-
ence of comorbidities, such as cardiovascular diseases, dia-
betes, and depression [12]. The study also concurred that 
whereas both sexual symptoms were associated with low 
total and free testosterone, there was a higher correlation 
with the decrease of libido than with ED [13]. 
Although the relationship between sexual symptoms 
and decreased testosterone may seem intuitive, the diffi-
culty in delineating the clinical boundaries of the age-asso-
ciated decrease in testosterone is confounded by the fact 
that several nonsexual age-related symptoms and diseases 
are also associated with decreased testosterone to a vary-
ing degree. Testosterone deficiency has been associated 
with decreased muscle mass [14], decreased bone mineral 
density [15-17], and increased risk of cardiovascular dis-
ease, type 2 diabetes, and metabolic syndrome [18]. 
Increase of inflammatory cytokines and changes toward 
unfavorable lipid profiles are associated with the incidence 
of atherosclerosis and cardiovascular disease and even-
tually increased mortality [18]. 
However, the array of features is not usually presented 
in a uniform profile of a typical hypogonadal patient. In a 
cross-sectional cohort study of 434 patients, excluding pa-
tients who received previous therapy for hypogonadism 
and selecting for ages above 50, Zitzmann et al attempted 
to define categorical groups of features [19]. Although the 
prevalence of sexual symptoms, such as libido and vigor, 
significantly differed at testosterone levels of 430 ng/dl (15 
nmol/l), metabolic and psychosomatic risk factors accumu-
lated with decreasing testosterone levels. ED contributed 
to the symptoms only below 230 ng/dl (8 nmol/l). The study 
also suggested a syndromic association through cluster 
analysis, whereby patients could distinctively be grouped 
into clusters characterized by psychosomatic complaints, 
metabolic disorders, or sexual health problems on the basis 
of testosterone level, age, and body mass index. Analysis 
revealed three clusters characterized as being predom-
inantly psychosomatic, metabolic and psychosomatic, and 
predominantly ED. The European Male Aging Study, a 
cross-sectional survey of 3,369 men (range, 40 to 79 years) 
from a random population, also suggested a syndromic as-
sociation with decreased testosterone levels [13]. Although 
symptoms of poor morning erection, low sexual desire, ED, 
inability to perform vigorous activity, depression, and fa-
tigue were all significantly related to testosterone level, on-
ly the three sexual symptoms had a syndromic association 
with decreased testosterone levels. Incorporating low tes-
tosterone levels, morning erections, ED, and decreased 
sexual thoughts showed a clustering of patients. 
Furthermore, two or more of the three symptoms had an 
increased odds ratio compared with single symptoms com-
bined with higher power of exclusion by testosterone. 
Owing to the difficulty in delineating a clear-cut patient 
group, earlier studies used the questionnaires available at 
the time [20]. Diagnostic tools such as the Aging Male 
Survey and the Saint Louis University Androgen 
Deficiency in Aging Males are highly sensitive but sub-
optimal in specificity [21-23]. The International Society for 
the Study of the Aging Male (ISSAM) and the Endocrine 
Society both recommend against the use of questionnaires 
because of this lack of specificity and suggest instead a for-
mal method of symptom assessment [6,7]. However, even 
this approach has been criticized as being equally in-
effective in improving specificity [23,24]. Recently, newer 
diagnostic tools, such as the European Male Aging Study 
Sexual Function Questionnaire [13,25] and the New 
England Research Institute hypogonadism screener 
Screener) have specifically been structured to meet the 
needs of diagnosing LOH [26]. These tests boast good corre-
lation with serum total testosterone as well as high 
specificity. Whether these newer tools can assist in clarify-
ing the diagnostic presentation of LOH requires further 
validation.Korean J Urol 2011;52:725-735
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2. Difficulty in determining LOH by biochemical levels of 
testosterone
The testis secretes more than 95% of circulating testoster-
one in the male, producing up to 6 to 7 mg per day [27]. 
Biosynthesis takes place within the Leydig cells, stimu-
lated by luteinizing hormone. In the serum, testosterone 
is mainly bound to albumin (50%) and sex hormone–bind-
ing globulin (SHBG, 45%), leaving only a small physiologi-
cally active free fraction [28]. However, testosterone binds 
loosely to albumin, making this testosterone and free tes-
tosterone available to tissues, i.e., bioavailable testoste-
rone. Testosterone is tightly bound to SHBG, rendering it 
biologically inactive.
The difficulty in presenting a cohesive diagnosis of LOH 
on the basis of biochemically defined levels of serum testos-
terone lies with the complexity by which testosterone is 
regulated and actuates function. Beginning with variables 
associated with determining the level of biologically active 
testosterone as a result of the fluctuating amounts of SHBG 
produced, as well as tissue responsiveness to testosterone 
depending on site, the activity of the androgen receptor and 
the expression of the androgen receptor itself all function 
to present a clinical picture not easily represented by bio-
available testosterone or total testosterone. 
Several factors are associated with the regulation of 
SHBG. In humans, SHBG is produced by hepatocytes [29]. 
Hepatocytes are the primary site of plasma SHBG biosyn-
thesis [30]. Thyroid and estrogenic hormones and a variety 
of drugs, including the anti-estrogen tamoxifen, the phy-
toestrogen genistein, and mitotane, increase SHBG 
production. In contrast, monosaccharides effectively de-
crease production by inducing lipogenesis, and production 
is influenced by hormonal, metabolic, and even nutritional 
status [31]. Furthermore, SHBG has been shown to have 
signaling function of its own; SHBG activates cAMP-medi-
ated pathways associated with a variety of downstream ef-
fects, including estrogen-induced androgen receptor acti-
vation of prostate-specific antigen (PSA) gene transcrip-
tion and cancer growth and inhibition [32]. It is clear that 
several factors are interconnected with the level of plasma 
SHBG, which in turn is closely associated with functional 
levels of testosterone. It is all the more important in the eld-
erly, in whom the factors that affect SHBG accumulate. 
Epidemiologic studies show that whereas the level of total 
testosterone gradually decreases with age, the level of free 
testosterone decreases more sharply [33]. 
The androgen receptor is also subject to various forms of 
effect modification both in tissue-wise distribution and in 
its molecular activity and expression. The main component 
that imbues variability to the function of testosterone in 
the cell is its conversion to a more metabolically active form, 
dihydrotestosterone, or its aromatization to estrogen. 
Dihydrotestosterone, although similar in interactions 
with testosterone on the androgen receptor, differs in an-
drogen receptor and coactivator motif interactions [34]. 
Aromatization to estrogen has been implicated in various 
age-related adiposity-increasing mechanisms and behav-
ioral changes [35]. These differing potencies are thus in 
part reliant on the conversion ability of each tissue, organ, 
or individual, whereas the activities of 5α-reductase or ar-
omatase are dependent on various conditions or drugs, 
most notably 5α-reductase inhibitors and anticonvulsants 
[36]. Other modifications, evident through androgenic 
anabolic steroids and selective androgen receptor modu-
lators, are some examples of the variability of pre-receptor 
activity modification that is possible [37].
Finally, the androgen receptor has been shown to have 
various modifications through coactivators or genetic 
mutations. Coactivators are proteins that enhance li-
gand-dependent transcriptional activity. As stated above, 
the affinity of dihydrotestosterone derives in part from dif-
ferent activities pertaining to coactivators. Several co-
activators with various functions have been found, and 
their specific activities are currently under investigation 
[38]. The most studied androgen receptor genetic muta-
tions affecting pathophysiologic presentations have been 
the polymorphism of CAG repeats. The mutations vary in 
length of between 18 and 24 tandem repeats that influence 
expression. These mutations have been implicated in a va-
riety of pathologic states, including androgen insensitivity 
syndrome, genetic muscular atrophy diseases, and even 
prostate cancer, whereas normal variations have been im-
plicated in explaining racial differences in the incidence of 
these pathologic states [38,39].
The complexity of physiologic regulation has led to a diffi-
culty in determining appropriate reference levels for diag-
nosing LOH. Testosterone is known to have a circadian var-
iation, reaching peak values in the morning; however, this 
circadian variation is blunted with aging [40]. Both ISSAM 
and the Endocrine Society recommend early morning 
timed measurement of total testosterone, between 700 and 
1100 [6,7], because some studies showed that intra-in-
dividual variation remained relatively consistent, despite 
wide inter-individual variation in the emergence of symp-
toms [41]. However, other studies presented wide weekly 
and between-day intra-individual variation greater than 
within-day intra-individual variation [40,42]. 
Further complicating the issue is that the physiologi-
cally optimal form of diagnosis is also impractical to 
implement. Despite the fact that numerous reports have 
substantiated that free testosterone better correlates with 
symptoms of LOH, free testosterone is difficult to measure 
and standardize [40,42]. The gold standard for determi-
nation of free testosterone is equilibrium dialysis [43]. 
However, equilibrium dialyses are costly, requiring more 
expertise and time than is considered feasible for local labo-
ratories [44]. Vermeulen et al introduced the method of cal-
culating bioavailable testosterone on the basis of measure-
ments of total testosterone, SHBG, and albumin [43]. 
These values correlate well with those obtained by equili-
brium dialysis, presenting a practical alternative, yet this 
method requires measurement of both total testosterone 
and SHBG. Hence, the standard recommendation for de-
creased levels of testosterone is an arbitrary balance be-Korean J Urol 2011;52:725-735
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TABLE 1. Evolution of guidelines for late-onset hypogonadism and testosterone replacement therapy
ISSAM
a Endocrine Society
Personal expert opinion
    1996
        Morales et al. Clinical practice guidelines for screening 
          and monitoring male patients receiving testosterone 
          supplementation therapy. Int J Impot Res
ISSAM official recommendations
    2002
        ISSAM recommendations. 
    2004
        ISA
b, ISSAM and EAU
c recommendations. 
        KOSAR Recommendations. Korean J Aging Male 2006, 
          Korean J Androl 2008
Evidence-based guidelines
    2008
      ISA, ISSAM, EAU, EAA
d and ASA
e recommendations.
      Park NC. Korean J Androl 2009
Evidence-based guidelines
    2006 
        Testosterone Therapy in Adult Men with Androgen 
          Deficiency Syndromes: An Endocrine Society Clinical 
          Practice Guideline. J Clin Endocrinol Metab 
    2010 
        Testosterone Therapy in Men with Androgen Deficiency 
          Syndromes: An Endocrine Society Clinical Practice 
          Guideline. J Clin Endocrinol Metab 
a: International Society for the Study of the Aging Male, 
b: International Society of Andrology, 
c: European Association of Urology, 
d: 
European Association of Andrology, 
e: American Society of Andrology
FIG. 1. Diagnostic algorithm for late-onset hypogonadism [95]. Recommendations by the ISSAM suggest a serum sample for total 
testosterone, taken between 700 and 1,100 hours, for patients who are at risk or suspected of hypogonadism. Total testosterone above 
12 nmol/l does not require treatment. Patients with serum total testosterone below 8 nmol/l will usually benefit from treatment. If 
the total testosterone is between 8 and 12 nmol/l, the measurement of total testosterone should be repeated with sex hormone-binding 
globulin to calculate free testosterone. Measurements of serum LH will assist in differentiating between primary and secondary 
hypogonadism. LH: luteinizing hormone, FSH: follicle stimulating hormone.
tween pragmatism and accuracy. The practical clinical 
steps of diagnosis would be to first estimate total testoster-
one and then to weigh the need to evaluate free testosterone 
levels by use of SHBG assays. 
With the confusion resulting from the inherent 
wide-reaching and varied nature of testosterone, several 
international organizations have presented guidelines 
and recommendations for the diagnosis and treatment of 
LOH (Table 1 and Fig. 1) [6,7]. 
The current ISSAM and Endocrine Society recom-
mendations agree that serum total testosterone below 230 
ng/dl (8 nmol/l) delineates a state of severe testosterone de-
ficiency and that correlating free testosterone measure-
ments of below 65 pg/ml (225 pmol/l) would assist in con-Korean J Urol 2011;52:725-735
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TABLE 2. Current available regimens for testosterone replacement therapy
Route Formulation Drug Dose Advantage Disadvantage
Oral
Buccal
Intramuscular
Subcutaneous
Transdermal
Capsule
Bioadhesive tablet
Oily suspension
Pellets/rods
Scrotal patch
Non scrotal patch
Gel
Testosterone
  undecanoate
Testosterone
Testosterone 
  enanthate
Testosterone 
  cypionate
Testosterone 
  undecanoate
Testosterone
Testosterone
40 mg, 4/d
30 mg, 2/d
250 mg, 
  1/2-3 wk
200 mg, 1/2 wk
1,000 mg, every 
  2-3 mo
3-6 (200 mg each) 
  every 6 mo
10-15 mg, 1/d
2.5-5 mg, 1/d
1%, 10 g/d
Convenience of oral 
  administration
Infrequent 
  administration
Infrequent 
  administration
Ease to stop 
  treatment
Ease to stop 
  treatment, ease of 
  application
Ease of application, 
  good skin 
  tolerability
Variable serum levels, 
  high DHT
a:T
b ratio
Gum related adverse 
  events in 16%
Wide variation of serum T
Large volume (4 ml) 
Requires surgical incision 
  for insertions
High DHT:T ratio, scrotal 
  shaving
Skin irritation
Potential transfer by 
  contact
a: dihydrotestosterone, 
b: testosterone
firming the diagnosis for total testosterone measurements 
below 350 ng/dl (12 nmol/l) [6,7]. While appreciating these 
guidelines, clinicians should be aware of the pitfalls sur-
rounding a biochemical diagnosis based on an arbitrary 
level of total testosterone as well as the disadvantage of 
lacking questionnaire tools that could aid in a cohesive ap-
proach to a syndromic pathology.
TESTOSTERONE REPLACEMENT THERAPY
There are several cautionary issues surrounding the prop-
er treatment of LOH. Despite the multiple steps at which 
the effect of testosterone may become diminished, at pres-
ent, there is no substantial evidence-based treatment for 
LOH other than replacement of the deficient hormone 
[6,7]. Furthermore, owing to the arbitrary nature of defin-
ing a diagnostic threshold of total testosterone as a mid to 
lower level in young men, patients may be subjected to un-
necessary testosterone replacement, complicated by the 
risk of increased testosterone levels possibly masking an 
underlying pathology [45]. 
The expected treatment outcome in LOH patients with 
testosterone replacement therapy is primarily improve-
ment of libido and erectile function [7]. With the un-
certainty over the effects of replacement, previous guide-
lines suggested that ideally testosterone replacement 
should mimic normal physiological circadian changes [46]. 
However, no substantial evidence has shown significant 
benefit of such a method, and subsequent recommenda-
tions do not support its necessity [6,7]. A number of natural 
testosterone replacements have been developed. Curren-
tly available routes of delivery consist of oral, buccal, intra-
muscular, and transdermal (patches and gels) routes 
(Table 2). There is no overall optimal therapeutic regimen. 
The clinician should consider the patient’s preference, 
pharmacokinetics, treatment burden, and cost when pre-
scribing treatment [7]. Considering the possibility of treat-
ing false-positive patients, clinical trials lasting 3 to 6 
months to observe for short-term improvement in sexual 
function is pertinent [47]. This trial of treatment is also 
beneficial for observing for adverse effects, because such 
cases warrant rapid discontinuation.
1. Libido 
Animal studies have demonstrated testosterone-related 
changes in the central nervous system. Neurophysiological 
studies of rats have shown that testosterone affects libido 
in the sexually dimorphic nucleus of the preoptic area [48]. 
A recent study demonstrated that, whereas middle-aged 
rats had significant impairments of sexual behavior com-
pared with young rats, castration and exogenous testoster-
one treatment restored sexual activity [35]. The study ob-
served that exogenous testosterone stimuli restored the 
androgen receptor density in the preoptic area to levels 
comparable to those of a young rat. 
There is some difficulty in assessing treatment effects on 
libido in the clinical setting. Studies comparing results in 
humans rely on subjective assessment of libido. Compari-
son of studies is difficult because of the differences in meth-
ods of treatment and response. However, several clinical 
trials have documented the effect of testosterone replace-
ment therapy in improving sexual desire. Several clinical 
trials showed consistent results of increased sexual fre-
quency and libido in hypogonadal men with testosterone Korean J Urol 2011;52:725-735
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replacement [49,50].
Other studies have noted varying responses to treat-
ment depending on the deficiency of testosterone before 
treatment. A meta-analysis of placebo-controlled trials re-
ported that most studies enrolling documented hypo-
gonadal patients showed improvement in libido [51]. The 
review noted, however, significant inconsistencies in the 
response to oral agents. Treatment in the low-normal 
range of testosterone for decreased libido also showed non-
significant or inconsistent effects on libido. A retrospective 
study of 211 men with various degrees of initial testoster-
one showed high response rates to total testosterone below 
300 ng/dl but considerably lower response to low-normal 
testosterone levels [52]. However, a recent placebo-con-
trolled, randomized double-blind study of otherwise-heal-
thy nonobese men with low-normal testosterone and symp-
toms of LOH reported improvement of libido after 12 
months [53]. The variable outcome among patients in the 
low-normal testosterone population may be due to under-
lying low bioavailable testosterone not evident in results 
shown by total testosterone. 
2. Erectile dysfunction
The classic etiology of ED consists of vascular, neurogenic, 
and psychological components. Recent studies have shown 
that ED, as a vascular phenomenon, is predictive of the de-
velopment of serious cardiovascular insults [54]. Other 
systemic conditions, such as diabetes and obesity, also me-
diate pathophysiologic changes that result in peripheral 
neuropathy or microvascular injuries that result in ED in 
a significant number of patients in these populations [55]. 
Conversely, studies have shown that the majority of pa-
tients with ED suffer from these comorbidities [56]. The 
large proportion of patients with systemic comorbidities in 
ED is clinically significant, considering that these patients 
are the main constituents of nonresponders to PDE5 in-
hibitors [57]. 
ED is also the most common sexual dysfunction in pa-
tients with LOH [12]. Animal studies and human cell cul-
ture studies have shown that hypogonadism exerts a sig-
nificant detrimental effect associated with peripheral 
mechanisms in the pathogenesis of ED. Testosterone has 
been shown to control commitment of penile stem cells to 
the smooth muscle cell lineage [58], whereas testosterone 
deprivation by castration results in reduced smooth mus-
cle content and increased connective tissue matrix [59]. 
Testosterone has also been shown to increase nitric oxide 
synthase transcription [60] and to maintain normal 
RhoA/Rho-kinase activity [61]. However, testosterone has 
also been shown to increase the expression of PDE5 [62]. 
Thus, testosterone induces an overall modest effect on erec-
tion alone, as observed in studies that found no significant 
association between ED and hypogonadism in normal 
healthy populations [63]. This dual function has been sug-
gested to allow testosterone to effectively regulate the tim-
ing of erection pertaining to sexual desire [58,64].
The complex association of the systemic etiology of ED, 
as well as the pervasive effect of testosterone in erection, 
suggested the possibility of improving the treatment of ED 
in hypogonadal patients by combined treatment with 
PDE5 inhibitors and testosterone replacement. Clinical 
studies began with ED patients who were refractory to 
PDE5 inhibitors [65]. The studies showed not only im-
proved overall sexual function with combination therapy, 
but most notably, improved erectile function presented as 
both components of subjective symptom scores and as 
physiologic indexes, such as resistive index values [65,66]. 
Studies have since shown various levels of success in erec-
tile function [67]. This may be because most of these clinical 
trials varied in their definition of testosterone deficiency 
as well as in the degrees of concomitant comorbidities, thus 
making it difficult to derive a conclusive target group in 
which combination therapy may benefit [67]. Both the low-
est reported success rate, 34%, and the highest, 100%, were 
from ED patients undergoing dialysis owing to renal fail-
ure [68]. Furthermore, the effect of testosterone does not 
seem to be uniform in these patients, as one study noted 
that the efficacy of combination therapy decreased as pa-
tients normalized in serum total testosterone [69]. Most of 
these studies were also limited in the length of treatment. 
Whereas early responses may be expected as late as 4 
weeks [70], studies have rarely extended beyond 12 weeks 
[66,69], at which point one study even noted a decline in effi-
cacy [69]. Hence, a longer period of observation of a more 
homogeneous cohort of patients is required to propound 
any definite conclusion. At present, combination therapy 
presents as a possible second-line treatment for patients 
failing PDE5 inhibitor monotherapy [71]. 
3. Adverse effects on the prostate
The most significant concern in prescribing testosterone 
replacement therapy is the effect on the prostate. Prostate 
tissue hypertrophy and progression to high-risk prostate 
cancer have been shown to be testosterone dependent [72]. 
The concern over the safety of testosterone replacement is 
understandable because androgen deprivation therapy is 
widely used to maintain prostate cancer regression [73]. 
However, observational studies have failed to find a corre-
lation between serum testosterone levels and prostate 
pathology. Studies of normal men without prostate cancer 
showed no correlation between PSA or prostate volume and 
testosterone [74]. Studies of benign prostatic hyperplasia 
(BPH) patients also showed no correlation between testos-
terone and International Prostate Symptom Score (IPSS) 
scores, PSA, and prostate volume [75]. Measurement of 
prediagnostic testosterone levels and surveillance of pros-
tate cancer also showed no additive effect of testosterone 
on cancer risk [76]. To address this concern, 18 study groups 
pooled patient data to identify prostate cancer risk against 
endogenous sex hormones [77]. The collected data repre-
sented 3,886 men with incident prostate cancer against 
6,438 controls. Analysis of the data suggested no evidence 
that serum concentrations of sex hormones were asso-
ciated with the risk of prostate cancer.Korean J Urol 2011;52:725-735
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TABLE 3. Guidelines for monitoring prostate safety during 
testosterone replacement therapy
Prostate cancer
    Contraindicated in P ca
a. or breast ca.
    Relatively CIx in high risk of developing P ca. 
    Unclear in localized low-grade (Gleason score ＜7) P ca.
    Successfully treated P ca. are potential candidates for   
    TRT after a prudent interval of no clinical or lab.  
    Evidence of residual ca. 
BPH
b
    Relative CIx in severe LUTS
c (high IPSS
d ＞21) for BPH 
    No CIx after successful Tx of lower urinary tract  obst.
Careful monitor for prostate safety during treatment 
    DRE
e, PSA
f
    Baseline, 3-6, 12 months and annually 
    Baseline, 3, 6, 9, 12 months and yearly in 2006
TR biopsies are indicated in sufficient high risk of P ca. 
    DRE: palpable prostate nodule or induration 
    PSA: ＞4 ng/ml 
        ＞3 ng/ml with high risk
        A baseline PSA ＞0.6 ng/ml 
    Age: ＞40 yr 
    F/Hx: first-degree relatives with prostate cancer.
    Ethnicity/race: African Americans 
No conclusive evidence  
    TRT increases the risk of P ca.  
    TRT convert subclinical  P ca. to clinically detectable P ca. 
    TRT increases the risk of BPH 
Unequivocal evidence 
    Testosterone can stimulate growth and aggravate symptoms 
      in locally advanced and metastatic P ca. 
a: prostate cancer, 
b: benign prostatic hyperplasia, 
c: lower 
Urinary tract symptoms, 
d: International Prostate Symptom 
Score, 
e: digital rectal examination, 
f: prostate specific antigen
Marks et al performed a randomized double-blind study 
in which hypogonadal men received testosterone or place-
bo and were observed for changes in prostate tissue testos-
terone after 6 months [78]. The study reported no change 
in histology, tissue markers, or gene expression specific to 
cancer and no significant changes in prostate volume, PSA, 
or voiding symptoms. Measurements of prostatic tissue 
testosterone levels remained at normal levels. Morgen-
taler and Traish suggested that the discrepancy between 
castration level testosterone inhibiting prostate cancer 
growth and normal levels not affecting incidence could be 
explained by the low threshold of androgen receptor bind-
ing achieving saturation [73]. They elaborated that testos-
terone exerts prostatic effects primarily by binding to the 
androgen receptor, and that maximal androgen–androgen 
receptor binding is achieved at serum testosterone concen-
trations well below the physiologic range. These ob-
servations suggest no clear correlation between testoster-
one replacement therapy and the incidence of prostate can-
cer, BPH, or progression of prostate cancer at normal se-
rum levels. There is also evidence that testosterone sup-
pression reduces growth or symptoms in men with ad-
vanced prostate cancer [72]. 
Despite the positive outlook for testosterone replace-
ment therapy against the risk of prostate malignancies, the 
evidence also cautions vigilance. Recently, the growth of 
prostate cancer cells affected by testosterone, or dihy-
drotestosterone, suggests possible cross-talk with EGF-re-
ceptors and downstream pathways inducing MAPK signal-
ing [79]. Through such nontranscriptional activities medi-
ated by cross-talk between pathways, testosterone may af-
fect a variety of physiologic functions including cell mo-
tility, metastasis, survival, and proliferation. Without 
clearly being able to discount these effects, cautious sur-
veillance for the risk of prostate cancer development is war-
ranted in patients receiving testosterone replacement 
therapy. The Endocrine Society recommends measure-
ment of PSA at the initiation of treatment and at 3 to 6 
months. An increase of the serum PSA concentration of 
more than 1.4 ng/ml within a 12 month period, a PSA veloc-
ity of higher than 0.4 ng/ml per year when observed for more 
than 2 years, detection of abnormalities on digital rectal ex-
amination, or an IPSS score above 19 should alert the urolo-
gist to consider the finding based on serum PSA and digital 
rectal exam when deciding on the need for a prostate 
biopsy. The ISSAM also recommends monitoring patients 
receiving testosterone treatment at 3 to 6 months, 12 
months, and then annually. Findings on the digital rectal 
exam and PSA indicate the need for a prostate biopsy. 
Relative contraindications include an IPSS scores higher 
than 21, which is associated with a risk for exacerbation 
of lower urinary tract symptoms or acute urinary retention 
(Table 3).
4. Concern for safety of other systems
The initial concerns during the recent rediscovery of testos-
terone replacement therapy primarily centered on the sig-
nificant adverse effects of previous androgen therapies. 
Abuse of synthetic androgens in high doses by athletes has 
led to documented side effects, including accumulation of 
lean body mass and fluid retention, gynecomastia, sleep 
apnea, and hepatitis [80]. Most of these side effects have 
been found to be associated with modified testosterone 
products with alkylation at the 17-hydroxy position, which 
leads to exacerbation of anabolic effects over androgenic ef-
fects, and are further complicated by overdoses up to 100 
times recommendations [81]. Alkylated androgens at high 
doses can cause hepatocellular and intrahepatic choles-
tasis that occasionally results in severe jaundice and hep-
atic failure. Peliosis hepatis, hepatocellular adenoma, and 
carcinoma may also result from the use of these compounds 
[82]. Because testosterone can be aromatized to estradiol 
in peripheral tissues, it occasionally induces mild gyneco-
mastia, most commonly in adolescents. However, aromati-
zation is common in men who take supraphysiologic doses 
of androgens, and these effects may persist for months after 
use of the alkylated agents has ceased [81]. Sleep apnea oc-
casionally develops or worsens during androgen-replace-
ment therapy [83], and erythrocytosis may also occur. Korean J Urol 2011;52:725-735
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With structural modifications, modern formulations 
prevent supraphysiological serum testosterone concen-
trations, thereby avoiding toxicologic risk to the liver. 
Gynecomastia is also rare under physiologic levels of tes-
tosterone [84]. Current guidelines include contraindica-
tion of therapy in case of breast cancer. Although sleep ap-
nea is a predominantly male disease, recent studies have 
failed to provide compelling evidence that testosterone re-
placement is associated [83]. Testosterone versus placebo 
studies have shown no changes in respiratory disturbance 
index or upper airway caliber [85].
However, testosterone replacement therapy has con-
sistently demonstrated stimulation of red blood cell 
production. The mechanism of action is through augmen-
tation of erythropoietin and direct effects of testosterone 
on erythroblasts in the bone marrow [86]. Although the oc-
currence of thromboembolism has not been reported in 
studies of testosterone replacement, current guidelines 
contraindicate the initiation of treatment in patients with 
a hematocrit above 52% [84].
The effects of testosterone on the lipid profile are still be-
ing debated. Khaw et al followed 11,606 men aged 40 to 79 
years in a nested case-control study and found that mean 
testosterone concentrations were lower in men who died of 
any cause, cardiovascular disease, or cancer than in control 
subjects [87]. Men who died of cardiovascular causes also 
had significantly higher mean body mass index, serum cho-
lesterol, and low-density lipoprotein (LDL):high-density 
lipoprotein (HDL) cholesterol ratios. Testosterone concen-
trations were significantly inversely related to body mass 
index, waist-hip ratio, triglycerides, and the prevalence of 
diabetes mellitus and were positively related to total cho-
lesterol, LDL cholesterol, and HDL cholesterol concen-
trations and to cigarette smoking. A meta-analysis of tes-
tosterone replacement pooled data from 29 randomized 
clinical trials and suggested that testosterone replacement 
reduced total cholesterol, with no change in LDL cholester-
ol [88]. There was also a reduction of HDL cholesterol, 
which was only found in studies with higher mean testos-
terone levels at baseline. 
Testosterone has shown improvements in short-term 
cardiovascular function either directly or indirectly 
through aromatization [89]. Animal studies have also 
shown testosterone to have an acute effect in dilatation of 
the coronary and pulmonary arteries. It is believed that tes-
tosterone causes both endothelium-dependent and endo-
thelium-independent vasodilatation. The former is ach-
ieved by an increased release of nitric oxide from the endo-
thelium, whereas the latter is caused by blocking of calcium 
channels or opening of potassium channels [90]. A 
short-term study of testosterone in 12 men with coronary 
artery disease or proven myocardial infarction showed sig-
nificant changes in improvement in ischemic threshold pa-
rameters [89]. Furthermore, this study showed concurrent 
evidence of total cholesterol and serum tumor necrosis fac-
tor-α  reduction. A more recent trial studied the effects on 
ischemia for 12 months with a randomized parallel group 
control trial [91]. At the end of follow-up, the testosterone 
group showed increased time to ischemia and decreased se-
rum triglycerides and body mass index, with no significant 
effects on serum HDL. 
Testosterone is also an important modulator of insulin 
sensitivity. Several clinical studies showed improved glu-
cose metabolism in testosterone versus placebo trials of hy-
pogonadal diabetic men [92-94]. Kapoor et al performed a 
double-blind cross-over study on 24 men with hypogonad-
ism and type 2 diabetes [93]. Treatment periods lasted ap-
proximately 3 months. Testosterone therapy improved 
fasting insulin sensitivity and reduced glycated hemoglo-
bin, fasting blood glucose, and total cholesterol as well as 
visceral adiposity as assessed by waist circumference and 
waist-hip ratio [94]. 
Currently, the overall effect of testosterone replacement 
has not been clearly established beyond safety under the 
recommended indications. Further investigations are re-
quired to claim any definite improvements to other asso-
ciated systems. 
CONCLUSION
Testosterone plays a significant role in the well-being of 
older men. Accumulating evidence even suggests a more 
vital role of testosterone replacement than improving the 
quality of life. Studies have consistently shown that testos-
terone deficiency leads to loss of libido and deteriorating 
erectile function, whereas replacement in testoster-
one-deficient patients provides symptomatic relief and 
improvement.
Because the diagnosis is not clearly delineated with an 
absolute biochemical threshold or pathognomic signs and 
symptoms, the early treatment period should be assessed 
for clear improvement of hypogonadic features. Although 
this may seem foreboding, such a recommendation merely 
dictates that therapy be accompanied by a short trial period 
with vigilance against possible adverse effects or under-
lying diseases. If there is no apparent danger of continuing 
treatment, maintaining and monitoring therapy within 
guidelines may significantly improve the patient’s quality 
of life and well-being. 
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